MedTrace Logo

Liver Damage and Cardiometabolic Disorders in NAFLD

NCT04036357 · Status: RECRUITING · Type: OBSERVATIONAL · Enrollment: 2000

Last updated 2019-08-16

No results posted yet for this study

Summary

Liver fibrosis is the most important prognostic factor in patients with non-alcoholic factor disease. Clinical and biological condition, as diabetes or mutation for PNPLA3, are well known factors associated with liver fibrosis onset and progression. However, little is known about biochemical factors predicting liver fibrosis evolution in large NAFLD populations.

Conditions

Sponsors & Collaborators

  • University of Roma La Sapienza

    lead OTHER

Principal Investigators

  • Maria Del Ben, MD · University of Roma La Sapienza

  • Daniele Pastori, MD · University of Roma La Sapienza

  • Francesco Baratta, MD · University of Roma La Sapienza

  • Francesco Angelico, MD · University of Roma La Sapienza

Eligibility

Min Age
18 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2011-11-30
Primary Completion
2036-12-31
Completion
2036-12-31

Countries

  • Italy

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04036357 on ClinicalTrials.gov